Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

This trial is testing a combination of two drugs — atezolizumab (an immunotherapy) and cabozantinib (a targeted therapy) — in patients with glioblastoma, the most aggressive form of brain cancer, whose tumor has come back after standard treatment. **You may be eligible if...** - You are 18 or older with confirmed glioblastoma or gliosarcoma that has recurred - You previously completed radiation and temozolomide chemotherapy - You are at least 12 weeks past your chemoradiation treatment - You have a Karnofsky Performance Score of at least 60 (able to care for yourself) - Your blood counts and organ function are adequate **You may NOT be eligible if...** - You have received prior immunotherapy targeting PD-1/PD-L1 or anti-VEGF drugs - Your cancer has spread outside the brain or has multiple disconnected tumor sites - You have an active autoimmune disease (with certain exceptions) - You have active infections, serious heart or lung disease, or a history of bowel perforation - You have had a recent stroke, heart attack, or significant surgery within 28 days - You are pregnant or breastfeeding - You are unable to swallow tablets Talk to your doctor to see if this trial is right for you.